Friday, Apr 27 2018 | Time 00:30 Hrs(IST)
image
image image
Science Technology Share

Circassia gives up on allergy after house dust mite study fails"

Circassia gives up on allergy after house dust mite study fails"

LONDON, Apr 18 (Reuters) Britain's Circassia Pharmaceuticals is throwing in the towel on allergy investment after a second high-profile clinical trial flop, focusing instead on building a broader respiratory business.The failure of the company's immunotherapy to perform better than placebo in fighting dust mite allergy in a Phase IIb test follows similar negative results in a Phase III trial against cat allergy last year. The company's stock lost two-third's of its value in a single session on the June 2016 cat results, which many investors feared undermined the allergy thesis, and the reaction on Tuesday was more muted, with shares losing around 3 percent. In both cases, the company said, the immunotherapy failed because of a marked placebo effect among patients not on therapy. The top shareholders in Circassia, which listed on the London stock market in March 2014 in Britain's largest biotech flotation for decades, are Invesco and Neil Woodford's investment management company, both big backers of UK science. Woodford suffered another setback earlier this month when Allied Minds, which commercialises ideas from universities, announced a large writedown. Circassia Chief Executive Steve Harris said he was "naturally disappointed" by the dust mite study failure. "We remain convinced that the technology has biologic activity, but we also believe the difficulty in overcoming the placebo effect using the field study designs required by regulators represents a significant hurdle, and consequently we will make no further investment in our allergy portfolio," he said. Instead, Circassia will concentrate on its wider respiratory business, in particular a new U.S. commercial collaboration with AstraZeneca. Circassia last month secured U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease for up to $230 million. REUTERS RJ

More News
World Immunization Week 2018: Protected Together, #VaccinesWork

World Immunization Week 2018: Protected Together, #VaccinesWork

25 Apr 2018 | 11:35 AM

Cairo, Apr 25 (UNI) This year’s World Immunization Week campaign, celebrated from April 24 to 30, aims to highlight that protecting entire communities with vaccines protects everyone and so the theme of this year’s campaign is “Protected Together, #VaccinesWork”.

 Sharesee more..
Immunization one of world’s most successful and cost-effective health interventions

Immunization one of world’s most successful and cost-effective health interventions

23 Apr 2018 | 1:01 PM

Kolkata, Apr 23 (UNI) Immunization saves millions of lives and is widely recognized as one of the world’s most successful and cost-effective health interventions.

 Sharesee more..
Revised SAGE recommendation on use of dengue vaccine

Revised SAGE recommendation on use of dengue vaccine

21 Apr 2018 | 12:57 PM

Kolkata, Apr 21 (UNI) Dengue is the most frequent and rapidly spreading mosquito-borne virus
Dengue virus is transmitted by female mosquitoes mainly of the species Aedes aegypti and, to a lesser extent, Ae.

 Sharesee more..
Mosquito-packed drones ready to join fight against Zika

Mosquito-packed drones ready to join fight against Zika

20 Apr 2018 | 7:09 PM

United Nations, Apr 20 (UNI) Robotics may soon be a critical ally in the fight against disease-spreading bugs, a United Nations agency has said after a successful test releasing sterile mosquitos from aerial drones as part of efforts to suppress the insect that spreads Zika and other diseases.

 Sharesee more..
Evidence shows banning asbestos has no negative economic impact

Evidence shows banning asbestos has no negative economic impact

20 Apr 2018 | 11:56 AM

Kolkata, Apr 20 (UNI) Sound scientific evidence shows that any exposure to asbestos fibres poses significant health risks.

 Sharesee more..
image